Table 2.
Adverse Events, Serious or Life-threatening Adverse Events (grades 3/4), and Key Laboratory Abnormalities (n=11) occurring in at least two patients OR greater than grade 2 are included.
| A051202 | A051202 | |||||
|---|---|---|---|---|---|---|
| Grade 1–2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3 | Grade 4 | |
| Anemia | 2 (67%) | 0 | 0 | 6 (75%) | 0 | 0 |
| Lymphocyte count decreased | 2 (67%) | 0 | 0 | 2 (25%) | 5 (63%) | 1 (13%) |
| Neutrophil count decreased | 1 (33%) | 1 (33%) | 0 | 4 (50%) | 1 (13%) | 0 |
| Platelet count decreased | 3 (100%) | 0 | 0 | 3 (38%) | 1 (13%) | 0 |
| White blood cell decreased | 2 (67%) | 0 | 0 | 3 (38%) | 0 | 0 |
| Constipation | 0 | 0 | 0 | 3 (38%) | 1 (13%) | 0 |
| Diarrhea | 0 | 0 | 0 | 3 (38%) | 0 | 0 |
| Mucositis oral | 2 (67%) | 0 | 0 | 1 (13%) | 0 | 0 |
| Fatigue | 2 (67%) | 0 | 0 | 6 (75%) | 1 (13%) | 0 |
| Fever | 1 (33%) | 0 | 0 | 3 (38%) | 1 (13%) | 0 |
| Lung infection | 0 | 0 | 0 | 0 | 2 (25%) | 0 |
| Alanine Aminotransferase increased | 0 | 1 (33%) | 1 (33%) | 5 (63%) | 0 | 0 |
| Alkaline phosphatase increased | 0 | 0 | 0 | 2 (25%) | 0 | 0 |
| Aspartate aminotransferase increased | 1 (33%) | 0 | 1 (33%) | 3 (38%) | 0 | 0 |
| Hyperglycemia | 0 | 0 | 0 | 2 (25%) | 1 (13%) | 0 |
| Hyperuricemia | 0 | 0 | 0 | 2 (25%) | 0 | 0 |
| Hypoalbuminemia | 1 (33%) | 0 | 0 | 3 (38%) | 0 | 0 |
| Hypocalcemia | 2 (67%) | 0 | 0 | 1 (13%) | 0 | 0 |
| Hyponatremia | 0 | 0 | 0 | 2 (25%) | 0 | 0 |
| Hypophosphatemia | 1 (33%) | 0 | 0 | 2 (25%) | 1 (13%) | 0 |
| Rash maculopapular | 0 | 2 (67%) | 0 | 1 (13%) | 4 (50%) | 0 |